单位：[1]Department of Respiratory Diseases, China-Japan Friendship Hospital,Peking University, Beijing, China[2]Department of Respiratory Medicine, RespiratoryResearch Institute, First Affliated Hospital of Guangzhou Medical College, Guang-zhou, China[3]Department of Respiratory Disease, Shanghai Changzheng Hospital,Second Military Medical University, Shanghai, China[4]Institute of RespiratoryDiseases, First Hospital, China Medical University, Shenyang, China[5]ChronicAirway Diseases Laboratory, Department of Respiratory and Critical Care Medicine,Nanfang Hospital, Southern Medical University, Guangzhou, China[6]Department ofPulmonary and Critical Care Medicine and Beiing Institute of Respiratory Medicine,Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China北京朝阳医院[7]Statisticsand Programming, AstraZeneca Japan, Osaka, Japan[8]Medical and Regulatory Af-fairs, AstraZeneca China, Shanghai, China[9]Respiratory Research Institute, FirstAffiliated Hospital of Guangzhou Medical College, Guangzhou, China.
Background: In the Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia, the effectiveness of single-inhaler budesonide/formoterol maintenance and reliever therapy was evaluated in patients with poorly controlled asthma. Objective: To study the effects of this therapy on a Chinese patient subgroup. Methods: In this 12-week, multicenter, open-label therapeutic phase IV study, patients with partially controlled or uncontrolled asthma were switched from their usual asthma treatment to budesonide/formoterol (160/4.5 mu g, one inhalation twice daily and as needed) after a 2-week run-in period. Primary and secondary objectives of the study, asthma control and quality of life were assessed by using the five-item Asthma Control Questionnaire and the Standardized Asthma Quality of Life Questionnaire. Asthma symptom scores, study medication use, asthma control and/or symptom-free days, and the number of asthma-related nighttime awakenings were also monitored. Results: In total, 478 Chinese patients were enrolled and 407 patients initiated treatment. The patients displayed a significant improvement in mean (standard deviation) five-item Asthma Control Questionnaire (-0.58 +/- 0.86; p < 0.0001) and Standardized Asthma Quality of Life Questionnaire (0.69 +/- 0.79; p < 0.0001) scores versus the run-in period. Mean (standard deviation) asthma symptom scores were significantly reduced compared with run-in (-0.30 +/- 0.55 daytime, -0.31 +/- 0.56 nighttime; p < 0.0001 for both), as was as-needed study medication use (-0.24 +/- 1.16 daytime, -0.28 +/- 0.97 nighttime; p < 0.0001 for both). Patients who received previous treatment with salmeterol/fluticasone propionate also showed improvement in asthma control. Conclusions: In China, asthma control in Chinese patients whose asthma was not fully controlled with previous standard therapy improved during 12 weeks of treatment with budesonide/formoterol maintenance and reliever therapy. Quality of life was improved, and treatment was well tolerated.
第一作者单位：[1]Department of Respiratory Diseases, China-Japan Friendship Hospital,Peking University, Beijing, China
通讯作者：
通讯机构：[9]Respiratory Research Institute, FirstAffiliated Hospital of Guangzhou Medical College, Guangzhou, China.[*1]Respiratory Research Institute, First Affiliated Hospital of Guangzhou, Medical College, 195 Dongfeng Xi Road, 510182 Guangzhou, China
推荐引用方式(GB/T 7714)：
Lin Jiangtao,Tang Yan,Xiu Qingyu,et al.Real-life effectiveness of budesonide/formoterol therapy in asthma: A subanalysis of the SMARTASIA study[J].ALLERGY and ASTHMA PROCEEDINGS.2016,37(1):27-34.doi:10.2500/aap.2016.37.3910.
APA：
Lin, Jiangtao,Tang, Yan,Xiu, Qingyu,Kang, Jian,Cai, Shaoxi...&Zhong, Nanshan.(2016).Real-life effectiveness of budesonide/formoterol therapy in asthma: A subanalysis of the SMARTASIA study.ALLERGY and ASTHMA PROCEEDINGS,37,(1)
MLA：
Lin, Jiangtao,et al."Real-life effectiveness of budesonide/formoterol therapy in asthma: A subanalysis of the SMARTASIA study".ALLERGY and ASTHMA PROCEEDINGS 37..1(2016):27-34
